13β-ethyl-3-methoxy-17α-allylaminomethylgona-2,5(10)-dien-17β-ol | 69269-31-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 13β-ethyl-3-methoxy-17α-allylaminomethylgona-2,5(10)-dien-17β-ol
• 英文别名: (8R,9S,13S,14S,17S)-13-ethyl-3-methoxy-17-[(prop-2-enylamino)methyl]-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-ol
• CAS: 69269-31-4
• 化学式: C₂₄H₃₇NO₂
• 分子量: 371.563
• InChiKey: NEEBMQPBNOZAGK-URYYLNOGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  13β-ethyl-3-methoxy-17α-allylaminomethylgona-2,5(10)-dien-17β-ol 、 碳酸二乙酯 在 potassium tert-butylate 作用下， 以43%的产率得到(8R,9S,13S,14S,17S)-13-ethyl-3-methoxy-3'-((Z)-prop-1-en-1-yl)-1,4,6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,5'-oxazolidin]-2'-one
  参考文献：
  名称：

  Synthesis of new spiro-steroids, II: Steroid-17-spiro-oxazolidinones*1

  摘要：

  New, potential aldosterone blocking 17-spiro-oxazolidinone derivatives with androstane, estrane and 13 beta-ethyl-gonane ring system were synthesized. 17S-Spiro-oxiranes were used as starting compounds and the oxazolidinone ring was built up in different ways. All compounds but one were devoid of considerable endocrine activities. 3-Oxo-13 beta-ethyl-gona-4,9(10),11-triene-17S-spiro-5'-(2'-oxo-3'-methyl)oxazolidine shows significant antiandrogen activity on s.c., but none on p.o. administration.

  DOI：

  10.1016/0039-128x(80)90138-5
• 作为产物：
  描述：

  13β-ethyl-3-methoxy-gona-2,5(10)-diene-17S-spiro-oxirane 、 丙烯胺 在 对甲苯磺酸 作用下， 以74%的产率得到13β-ethyl-3-methoxy-17α-allylaminomethylgona-2,5(10)-dien-17β-ol
  参考文献：
  名称：

  Synthesis of new spiro-steroids, II: Steroid-17-spiro-oxazolidinones*1

  摘要：

  New, potential aldosterone blocking 17-spiro-oxazolidinone derivatives with androstane, estrane and 13 beta-ethyl-gonane ring system were synthesized. 17S-Spiro-oxiranes were used as starting compounds and the oxazolidinone ring was built up in different ways. All compounds but one were devoid of considerable endocrine activities. 3-Oxo-13 beta-ethyl-gona-4,9(10),11-triene-17S-spiro-5'-(2'-oxo-3'-methyl)oxazolidine shows significant antiandrogen activity on s.c., but none on p.o. administration.

  DOI：

  10.1016/0039-128x(80)90138-5

文献信息

• US4180505A
  申请人：——

  公开号：US4180505A

  公开（公告）日：1979-12-25